Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
Dexrazoxane has been approved to treat anthracycline-induced cardiomyopathy and extravasation. However, the effect of dexrazoxane on epirubicin-induced genetic alterations in germ cells has not yet been reported. Thus, the aim of this study was to determine whether dexrazoxane modulates epirubicin-induced genetic damage in the germ cells of male mice. Our results show that dexrazoxane was not genotoxic at the tested doses. Furthermore, it protected mouse germ cells against epirubicin-induced genetic alterations as detected by the reduction in disomic and diploid sperm, spermatogonial chromosomal aberrations, and abnormal sperm heads. The attenuating effect of dexrazoxane was greater at higher dose, indicating a dose-dependent effect. Moreover, sperm motility and count were ameliorated by dexrazoxane pretreatment. Epirubicin induced marked biochemical changes characteristic of oxidative DNA damage including elevated 8-hydroxy-2'-deoxyguanosine levels and reduction in reduced glutathione. Pretreatment of mice with dexrazoxane before epirubicin challenge restored these altered endpoints. We conclude that dexrazoxane may efficiently mitigate the epirubicin insult in male germ cells, and prevent the enhanced risk of abnormal reproductive outcomes and associated health risks. Thus, pretreating patients with dexrazoxane prior to epirubicin may efficiently preserve not only sperm quality but also prevent the transmission of genetic damage to future generations.
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.|Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.
Sabry M
http://orcid.org/0000-0001-8560-8944
SM
Attia
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
Sheikh F
SF
Ahmad
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
Mushtaq A
MA
Ansaria
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
Ahmed
A
Nadeem
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
Othman A
OA
Al-Shabanah
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
Mohammed M
MM
Al-Harbi
Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
Saleh A
SA
Bakheet
Proc Natl Acad Sci U S A. 1975 Nov;72(11):4425-9
1060122
N Engl J Med. 2004 Jul 8;351(2):145-53
15247354
Asian J Androl. 2006 Mar;8(2):143-57
16491265
Hum Reprod. 2007 Jul;22(7):1893-8
17575282
Cytogenet Genome Res. 2004;107(1-2):83-94
15305060
J Clin Biochem Nutr. 2010 Nov;47(3):238-45
21103033
Mutat Res. 2009 Feb 19;673(1):29-36
19095079
Biomed Pharmacother. 2010 Apr;64(4):259-63
19932589
Drugs. 1997;54 Suppl 4:1-7
9361955
Clin Cancer Res. 2005 May 15;11(10):3915-24
15897593
Cardiovasc Toxicol. 2002;2(2):111-8
12271154
J Inorg Biochem. 2000 Feb;78(3):209-16
10805177
Zygote. 1999 May;7(2):131-4
10418106
BMC Cancer. 2010 Jun 29;10:337
20587042
Biosci Rep. 1987 Aug;7(8):653-8
3480764
Oxid Med Cell Longev. 2010 Jul-Aug;3(4):238-53
20972370
Eur J Hum Genet. 2001 Dec;9(12):910-6
11840192
Mutat Res. 1973 Dec;20(3):403-16
4798362
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
10075079
Mutat Res. 1986 Mar;160(1):39-46
3456485
Mutagenesis. 2011 Jul;26(4):533-43
21430063
Mol Cancer Ther. 2009 May;8(5):1075-85
19417146
Arch Biochem Biophys. 1959 May;82(1):70-7
13650640
J Clin Oncol. 1992 Sep;10(9):1444-51
1517787
Environ Mol Mutagen. 1996;28(3):159-66
8908176
Teratog Carcinog Mutagen. 2002;22(4):257-69
12111710
Mutat Res. 2002 Sep 26;520(1-2):1-13
12297139
Mutagenesis. 2001 Jul;16(4):339-43
11420403
Mutat Res. 2012 Jan 24;741(1-2):22-31
22063162
Drug Resist Updat. 2001 Oct;4(5):303-13
11991684
Leuk Res. 2003 Jul;27(7):617-26
12681361
Ann Oncol. 2006 Apr;17(4):614-22
16423847
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003917
15674919
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Nat Rev Genet. 2012 Jan 24;13(3):189-203
22269907
Mutagenesis. 2016 Mar;31(2):137-45
26399706
Z Naturforsch C. 2010 Mar-Apr;65(3-4):211-7
20469640
CA Cancer J Clin. 2005 Jul-Aug;55(4):211-28; quiz 263-4
16020423
J Clin Oncol. 2005 Jun 20;23(18):4179-91
15961765
PLoS One. 2014 Oct 10;9(10):e109942
25303090
Mutat Res. 2000 Jul 10;468(2):109-15
10882889
Cancer Chemother Pharmacol. 2009 Sep;64(4):837-45
19184016
Free Radic Biol Med. 2000 Feb 15;28(4):529-36
10719234